Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2007HematologyOpen Access

Biology and Treatment of Primary Myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRonald HoffmanIcahn School of Medicine at Mount SinaiDRDamiano RondelliUniversity of Illinois Chicago

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hoffman et al. (2007) studied this question.

synapsesocial.com/papers/6a2035310a9d8fc05fd8deffhttps://doi.org/10.1182/asheducation-2007.1.346
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice2002 · 242 citations
  2. 2Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis2007 · 217 citations
  3. 3Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice2007 · 51 citations
  4. 4Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia2007 · 180 citations
  5. 5Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis2006 · 180 citations